{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-046314","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.465766+00:00","generated_at":"2026-05-30T00:52:03.274359+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026","bullets":["Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.","Phase 3 STRIVE-ON safety trial enrollment complete; data readout expected Q1 2025; NDA submission for GTx-104 on track for 1H 2025.","Cash and equivalents $15.1M; projected runway into Q2 2026.","Redomiciled to Delaware and rebranded to Grace Therapeutics; ticker changed to GRCE on Nasdaq.","Hosting KOL event on aSAH on Nov 20, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-046314","json":"https://secwatch.observer/filing/0001140361-24-046314.json","markdown":"https://secwatch.observer/filing/0001140361-24-046314.md","text":"https://secwatch.observer/filing/0001140361-24-046314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/0001140361-24-046314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:52:03.274359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}